ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder

Phase 4

Completed

Conditions: Overactive Bladder

Interventions: Biological: onabotulinumtoxinA
Drug: Normal saline

First Posted Date: 2013-09-18

Last Posted Date: 2017-11-06

Lead Sponsor: Allergan

Target Recruit Count: 254

Registration Number: NCT01945489

Locations: 🇺🇸
Genesis Research LLC, San Diego, California, United States
🇺🇸
Deaconess Clinic, Inc., Newburgh, Indiana, United States
🇺🇸
Urology Associates of Norwalk, Norwalk, Connecticut, United States

and more 36 locations

An Adult Spasticity Registry of OnabotulinumtoxinA Treatment

Completed

Conditions: Muscle Spasticity

Interventions: Drug: onabotulinumtoxinA

First Posted Date: 2013-08-29

Last Posted Date: 2019-02-11

Lead Sponsor: Allergan

Target Recruit Count: 744

Registration Number: NCT01930786

Locations: 🇺🇸
MS Center of California, Newport Beach, California, United States
🇪🇸
Hospital de Conxo (Santiago de Compostela) GALICIA, Santiago De Compestela, Pontevedra, Spain
🇺🇸
University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States

and more 52 locations

Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns

Phase 4

Completed

Conditions: Urinary Bladder Diseases
Multiple Sclerosis

Interventions: Behavioral: Systematic Screening and Education Regimen

First Posted Date: 2013-08-29

Last Posted Date: 2016-05-27

Lead Sponsor: Allergan

Target Recruit Count: 120

Registration Number: NCT01930799

A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema

Completed

Conditions: Retinal Vein Occlusion
Macular Edema

Interventions: Drug: Anti-VEGF

First Posted Date: 2013-08-07

Last Posted Date: 2019-04-18

Lead Sponsor: Allergan

Target Recruit Count: 323

Registration Number: NCT01918371

A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation

Phase 2

Terminated

Conditions: Premature Ejaculation

Interventions: Drug: Normal Saline
Drug: OnabotulinumtoxinA

First Posted Date: 2013-08-06

Last Posted Date: 2018-10-18

Lead Sponsor: Allergan

Target Recruit Count: 59

Registration Number: NCT01917006

Locations: 🇺🇸
Manhattan Medical Research, New York, New York, United States
🇬🇧
King's College Hospital, London, United Kingdom
🇬🇧
Celerion, Belfast, United Kingdom

and more 7 locations

A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

Phase 2

Completed

Conditions: Alopecia
Alopecia, Androgenetic
Baldness

Interventions: Drug: Bimatoprost Solution 1
Drug: Bimatoprost Solution 2
Drug: Bimatoprost Vehicle

First Posted Date: 2013-07-22

Last Posted Date: 2016-03-22

Lead Sponsor: Allergan

Target Recruit Count: 244

Registration Number: NCT01904721

A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion

Phase 4

Completed

Conditions: Retinal Vein Occlusion
Macular Edema

Interventions: Drug: dexamethasone implant

First Posted Date: 2013-07-19

Last Posted Date: 2019-04-17

Lead Sponsor: Allergan

Target Recruit Count: 71

Registration Number: NCT01903720

A Study to Compare the Safety and Efficacy of a New Eye Drop Formulation With REFRESH PLUS® in Participants Following LASIK Refractive Surgery

Phase 3

Completed

Conditions: Bilateral LASIK Surgery

Interventions: Drug: carboxymethylcellulose sodium based eye drops
Drug: carboxymethylcellulose sodium based new eye drop formulation

First Posted Date: 2013-06-26

Last Posted Date: 2019-04-16

Lead Sponsor: Allergan

Target Recruit Count: 148

Registration Number: NCT01886690

A Study to Determine the Prevalence of Inflammatory Dry Eye Disease in Patients Prior to Cataract Removal

Completed

Conditions: Dry Eye Syndromes

Interventions: Other: No intervention

First Posted Date: 2013-06-20

Last Posted Date: 2015-12-03

Lead Sponsor: Allergan

Target Recruit Count: 204

Registration Number: NCT01882413

An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Phase 4

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: bimatoprost 0.01%
Drug: travatan 0.004%
Drug: timolol 0.5%
Drug: hypromellose 0.3%

First Posted Date: 2013-06-19

Last Posted Date: 2015-11-30

Lead Sponsor: Allergan

Target Recruit Count: 93

Registration Number: NCT01881126

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy